Skip to content

This Week in Dermatology — Jul 24, 2026

July 25, 2026 · 8 min

Show notes

Editor's Pick: Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials (Nature medicine, 2026)

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning systemic therapeutics for inflammatory skin disease, diagnostic imaging innovations, and pediatric and supportive care. Let's dive in. We begin with major advances in systemic therapies for inflammatory conditions and cutaneous oncology.

This week's papers:

  1. Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials.. Nature medicine 2026
  2. Clinical and Dermoscopic Triage of head and neck Macules: The Role of Reflectance Confocal Microscopy in a Prospective Study of 2006 Lesions.. Journal of the American Academy of Dermatology 2026
  3. Comparative effects of interventions for rosacea across phenotype-relevant outcomes: a systematic review and network meta-analysis.. Journal of the American Academy of Dermatology 2026
  4. Insulin Resistance is Not a Predictor of Response to Low-Dose Oral Metformin Therapy in Patients with CCCA: A Retrospective Review.. Journal of the American Academy of Dermatology 2026
  5. Magnified ultraviolet-induced fluorescence dermatoscopy for assessing mite viability in scabies.. Journal of the American Academy of Dermatology 2026
  6. Initial Psychometric Validation of the Caregiver Atopic Dermatitis Control Tool.. Clinical and experimental dermatology 2026
  7. High Level of Uncertainty in Assigning Causative Medications in Drug Reaction with Eosinophilia and Systemic Symptoms: A Retrospective Cohort Analysis.. Journal of the American Academy of Dermatology 2026
  8. A Comprehensive Review of the Current Systemic Medical Treatment Landscape for Vascular Malformations.. Pediatric dermatology 2026
  9. Durable remission with no survival reduction after mogamulizumab discontinuation in Sézary syndrome.. The British journal of dermatology 2026
  10. Cutaneous leishmaniasis in patients in treatment with anti-TNF-α drugs. Study of 20 cases from a single institution.. Clinical and experimental dermatology 2026

Listen at AudioScholar

All episodes of AudioScholar Dermatology Weekly (India)

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.